Sandoz will establish global center of excellence at EBEWE site. Novartis is paying $1.2 billion in cash for Austria-based EBEWE Pharma’s specialty generic injectables business. The deal includes ...
BASEL, Switzerland The generics arm of drug maker Novartis has acquired part of a generics company focused on cancer treatment. Sandoz announced that it had acquired the specialty generic injectables ...
Novartis’ Sandoz division is buying the generic injectable oncology business of Austria’s EBEWE Pharma. Novartis’ Sandoz division is buying the generic injectable oncology business of Austria’s EBEWE ...
EBEWE Pharma, with its comprehensive range of important generic injectable medicines, provides Sandoz an opportunity to create a strategic generic oncology injectables business unit and strong global ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results